A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
Please note: the estimated primary completion date for this study of January, 2019 has passed. However, it is not listed as closed by ClinicalTrials.gov. Inquire with the study contacts (listed below) to determine if they are still accepting participants or for more information about the treatment protocol.
CA-170 is a rationally designed and orally available, small molecule that directly targets the Programmed death-ligands 1 and 2 (PD-L1/PD-L2), and V-domain Ig suppressor of T cell activation (VISTA) immune checkpoints and results in activation of T cell proliferation and cytokine production. This is a multi-center, open-label, Phase 1 trial of orally administered CA-170 in adult patients with advanced solid tumors or lymphomas who have progressed or are non-responsive to available therapies and for which no standard therapy exists.
- Added: February 25th, 2019.
- Last updated: February 25th, 2019.
Primary Outcome Measures
- The number of patients with a dose-limiting toxicity (DLT) in the first treatment cycle [ Time Frame: Approximately 24 months ]
- Maximum tolerated dose (MTD) of CA-170 [ Time Frame: Approximately 24 months ]
- Recommended Phase 2 Dose (RP2D) of CA-170 [ Time Frame: Approximately 24 months ]
Secondary Outcome Measures
- Pharmacokinetic (PK) Profile of CA-170 [ Time Frame: From Day 1 of Cycle 1(each cycle is 21 days) ]Maximum Concentration (Cmax)
- Pharmacokinetic (PK) Profile of CA-170 [ Time Frame: From Day 1 of Cycle 1(each cycle is 21 days) ]Area Under the Curve (AUC)
- Preliminary Anti-tumor Activity of CA-170 based on RECIST and Immune Related Response Criterion (irRC) for Solid Tumors or Cheson for lymphoma [ Time Frame: 36 months ]
- Males and females ≥ 18 years of age;
- Life expectancy of at least 3 months;
- ECOG PS ≤ 1;
- Acceptable bone marrow and organ function at screening;
- Ability to swallow and retain oral medications;
- Negative serum pregnancy test in women of childbearing potential;
- Measurable disease;
- tumor for which standard therapy, including approved anti-PD-1 or anti-PD-L1 therapy, when applicable, does not exist or is no longer effective. For patients enrolling into backfill of dose levels at or below the MTD/RP2D, patients with tumor types known to have a high VISTA expression (such as metastatic malignant pleural mesothelioma of epithelioid histology).
- Prior treatment anti-cancer therapy or use of any investigational agent within the past 28 days or 5 half-lives, whichever is shorter;
- Toxicity from prior chemotherapy that has not resolved to grade ≤ 1;
- Radiotherapy within the last 21 days;
- Primary brain tumors or CNS metastases;
- Major or minor surgery < 28 and <14 days from the start of treatment, respectively;
- Active autoimmune disease or any medical condition requiring the use of systemic immunosuppressive medications;
- Endocrinopathies, unless on stable hormone replacement therapy;
- Active infection requiring systemic therapy;
- Receipt of live vaccines against infectious diseases within 28 days;
- HIV positive or an AIDS-related illness;
- Active/chronic HBV or HCV infection;
- Uncontrolled CHF (NYHA Class 2-4), angina, MI, CVA, coronary/peripheral artery bypass graft surgery, TIA, or PE in prior 3 months;
- Cardiac dysrhythmias;
- Gastrointestinal disease that interferes with receipt of oral drugs;
- Concomitant malignancy;
- Pregnant or lactating female;
Source: the U.S. National Institutes of Health via ClinicalTrials.gov. Last updated: February 25th, 2019.
You can follow any responses to this entry through the RSS 2.0 feed.
Both comments and pings are currently closed.